Cytokinetics Inc vs Prospect Capital Corporation — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: Cytokinetics Inc is far larger — about 9.3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.93% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PSEC | |
|---|---|---|
Market Cap | $10.63B | $1.14B |
Sector | Technology | Financials |
52-Week High | $87.26 | $3.05 |
52-Week Low | $34.31 | $2.11 |
Enterprise Value | $10.74B | — |
Dividend Yield | — | 21.93% |
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →